Progen Restructures Manufacturing and Drug Discovery... ( BRISBANE Australia March 27 /- Pr...)

Progen Restructures Manufacturing and Drug Discovery Divisions

Date:3/27/2008

BRISBANE, Australia, March 27 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced that it will outsource the commercial manufacture of PI-88. The Progen manufacturing facility at the Brisbane suburb of Darra will be retained as a stand-alone business providing process development services and the manufacture of drug development material. Progen expects the transfer of PI-88 manufacture to occur in the next 12 to 18 months.

Progen will maintain the manufacturing facility with existing contracts as a break even operation, and will be assessing its options to either increase facility profitability through additional manufacturing contracts and/or seek a commercial buyer.

"Our manufacturing division has been of great value and has served Progen very well in the past, having made all PI-88 to date, including the supply to be used in the Phase 3 PATHWAY trial as well as having played and continuing to play an important role in supplying contract manufacturing services globally," said Progen's CEO, Justus Homburg.

"However, as far as PI-88 is concerned, the facility was never designed for the manufacture of commercial quantities, and we intend to contract out commercial PI-88 production to an established large-scale commercial bio-pharmaceutical manufacturer."

Further, following several years of in-house active drug development, the chemistry on newly identified lead compound PG545 has essentially been completed. PG545 has been selected for investigational new drug (IND) enabling studies, which are being outsourced.

The restructure involves 8 redundancies in the manufacturing division and 4 in drug discovery and aims to conserve current cash reserves for driving present and future Progen lead compounds towards commercialization.
In summary, following the decisions taken, Progen will:

-- Contract out the commercial supply of PI-88 to an established

bio-pharmace
'/>"/>

SOURCE Progen Pharmaceuticals Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related biology technology :

1. Progen Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference
2. Progeniq Joins Microsoft in Bio IT Alliance
3. Empire Genomics and Reprogenetics Join Forces to Improve Preimplantation Genetic Diagnosis (PGD)
4. Progentix Orthobiology B.V. Closes Series A Financing Round
5. Progen Expands Drug Development Pipeline Through Acquisition of CellGate
6. Progen Expands Board of Directors
7. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
8. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
9. CME LLC Restructures, Announces Its New Executive Management Team
10. Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
11. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility

Post Your Comments:

(Date:5/23/2013)... Pa. , May 23, 2013 ... research and advisory firms for specialized biopharmaceutical issues, ... hepatologists, and infectious disease specialists reported that in ... patients (e.g., intentionally delaying treatment) in anticipation of ... than six months ago, when only 6 percent ...

(Date:5/23/2013)... 2013 Northwest Biotherapeutics (NASDAQ: NWBO ... personalized immune therapies for solid tumor cancers, announced ... year,s American Society Of Clinical Oncology (ASCO) meeting in ... role in immune therapy. (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ... the pre-eminent conference focused on clinical treatment of cancer, ...

(Date:5/23/2013)... Verenium Corporation (Nasdaq: VRNM ), a ... commercialization of high-performance enzymes, today announced that ... at two upcoming conferences. (Logo: http://photos.prnewswire.com/prnh/20120924/MM79973LOGO ... Second Annual Marcum LLP Microcap Conference on Thursday, May ... York City. The presentation is scheduled to begin at ...

(Date:5/23/2013)... Tucson, Ariz. (PRWEB) May 23, 2013 ... world’s first and only FDA, Health Canada and CE ... Glasgow Science Centre in Scotland, which boasts more than ... Total Artificial Heart powered by the Freedom® portable ... one of the most advanced exhibitions of its kind. ...

Breaking Biology Technology:The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2 The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3 NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2 NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3 Verenium To Present At Two Upcoming Conferences 2 Verenium To Present At Two Upcoming Conferences 3 SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 2 SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 3

[0] The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments [0] NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer [0] Verenium To Present At Two Upcoming Conferences [0] SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre

... Genesis Biopharma, Inc. (OTC Bulletin Board: ... therapies, today announced the company,s support of the ... Two or More Unmarketed Investigational Drugs for Use ... companies to collaborate and seek approval for successfully ...

... Health, Inc. (Nasdaq: GHDX) today announced presentation of three ... (1) Gastrointestinal (GI) Cancer Symposium, including one finding that ... recurrence risk in stage II colon cancer, suggesting that ... Recurrence Score® (RS) test as well as T-stage and ...

... 21, 2011 NewLink Genetics Corporation today announced that ... the company,s investigational HyperAcute® Pancreas cancer immunotherapy will be ... of Clinical Oncology 2011 Gastrointestinal Cancers Symposium in San ... Title: Effect of the addition of ...

Genesis Biopharma Expresses Support for FDA Codevelopment Guidelines Genomic Health Announces Multiple Colon Cancer Studies at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium NewLink Genetics to Present Phase 2 Data of Its HyperAcute® Pancreas Immunotherapy at ASCO 2011 Gastrointestinal Cancers Symposium

(Date:5/24/2013)... conference of 500 leading water scientists from around the ... reforms, "in the short span of one or two ... Earth will be living under the handicap of severe ... for which there is no substitute. This handicap will ... The scientists bluntly pointed to chronic underlying problems led ...

(Date:5/23/2013)... Investigators at Rollins School of Public Health at ... Institute of Technology, have received a $4 million ... Center at Emory University (Health and Exposome Research ... first exposome-based center grant awarded in the United ... by the National Institute of Environmental Health Sciences ...

(Date:5/23/2013)... A new report from the Institute of Medicine ... in at least 60 minutes of vigorous or moderate ... than half of American youth meet current evidence-based guidelines ... intensity physical activity daily, according to the report, which ... school for nearly half of their waking hours, the ...

Breaking Biology News(10 mins):A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 2 A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 3 A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 4 Emory, Georgia Tech receive first human exposome center grant in US 2 Emory, Georgia Tech receive first human exposome center grant in US 3 Schools should provide students with daily physical activity, IOM recommends 2

[0] A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists [0] Emory, Georgia Tech receive first human exposome center grant in US [0] Schools should provide students with daily physical activity, IOM recommends

... The onset of inflammation and infection in a person recovering ... burns can be as deadly as the incident itself. New ... trauma victims may help to predict and better treat such ... issue of the journal PLoS Medicine shows for ...

... Alaska Natives in the Yukon River Basin provide unique ... adaptation strategies for these local communities. The ... the villages of St. Mary,s and Pitka,s Point, Alaska, ... concerns ranging from safety, such as unpredictable weather patterns ...

... at the San Diego Supercomputer Center (SDSC) at the ... the first global camera trap study of mammals, which ... of protected areas to ensure the diversity and survival ... study, led by Jorge Ahumada, an ecologist with the ...

Cached Biology News:Gene flux can foretell survival for trauma patients, Princeton study finds 2 Gene flux can foretell survival for trauma patients, Princeton study finds 3 Gene flux can foretell survival for trauma patients, Princeton study finds 4 Gene flux can foretell survival for trauma patients, Princeton study finds 5 Gene flux can foretell survival for trauma patients, Princeton study finds 6 Gene flux can foretell survival for trauma patients, Princeton study finds 7 Observations of climate change from indigenous Alaskans 2 Observations of climate change from indigenous Alaskans 3 SDSC-developed software used in first global camera trap mammal study 2 SDSC-developed software used in first global camera trap mammal study 3

Gene flux can foretell survival for trauma patients, Princeton study finds Observations of climate change from indigenous Alaskans SDSC-developed software used in first global camera trap mammal study

AVOID FREEZE/THAW CYCLES. Recognizes the ~32 kDa DNase IIα chain and the ~40 kDa proenzyme. DNase II causes both DNA condensation and DNA fragmentation. ...

BD BioCoat Poly-D-Lysine 60 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine....

... BD BioCoat Collagen I 60 mm Culture Dishes ... Dishes, tissue-culture treated polystyrene with a uniform application ... Coating : Collagen I ,Surface : ... 21.3 cm2 ,Dim nominal : 60 ...

... This CLS number is a new product ... number. If showing no availability yet, please ... or contact customer service for assistance. ... Comp Dim: D H 100 ...

Biology Products:

Rabbit Anti-Human DNase II Polyclonal Antibody, Unconjugated from Calbiochem BD BioCoat Poly-D-Lysine 60 mm Culture Dishes from BD Biosciences - Discovery Labware BD BioCoat Collagen I 60 mm Culture Dishes from BD Biosciences - Discovery Labware Corning C ulture Dishes,100X20 mm,55Cm2,Sterile,6-Pack Carrier (6Pks Of 10 Dishes) from Sigma-Aldrich